Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2697-2704

  Liu, Xuesong ^a   Powlas, Jessica ^a   Shi, Yan ^a   Oleksijew, Anatol X ^a   Shoemaker, Alexander R ^a   De Jong, Ron ^b   Oltersdorf, Tilman ^b   Giranda, Vincent L ^a   Luo, Yan ^a  

^a ABBOTT LABORATORIES   (United States)

^b PFIZER INC   (United States)

Author keywords

Akt; p70 S6 kinase; Phosphatidylinositol 3 kinase; PKB; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; S6 KINSE; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; EMBRYO; GENE ACTIVATION; GENE OVEREXPRESSION; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCID MOUSE; TISSUE CULTURE; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; ISOENZYMES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; NIH 3T3 CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 6444220198     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Datta SR, Brunei A and Greenberg ME: Cellular survival: a play in three Akts. Gene & Dev 13: 2905-27, 1999.
2. Franke TF, Yang S, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein kinase encoded by the akt proto-oncogene is a target of the PDGF-activated phosphotidylinositol 3-kinase. Cell 81: 727-36, 1995.
3. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Hoimes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J and Hawkins PT: Protein kinase B kinases that mediate phosphatidylinositol 3,4,5- triphosphate-dependent activation of protein kinase B. Science 279: 710-14, 1998.
4. Franke TF, Kaplan DR, Cantley LC and Toker A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-68, 1997.
5. Sable CL, Filippa N, Filloux C, Hemmings BA and Van Obberghen E: Involvement of the pleckstrin homology domain in the insulin-stimulated activation of protein kinase B. J Biol Chem 275: 29600-06, 1998.
6. Anjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW and Hemmings BA: Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proc Natl Acad Sci 93: 5699-704, 1996.
7. Kohn AD, Takeuchi F and Roth RA: Akt, a pleckstrin domain containing kinase, is activated primarily by phosphorylation. J Biol Chem 277: 21920-26, 1996.
8. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB and Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B Curr Biol 7: 261-69, 1997.
9. Hill MM, Feng J and Hemmings BA: Identification of a plasma membrane raft-associateed PKB ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 12: 1251-55, 2002.
10. Khwaja A: Akt is more than just a Bad kinase. Nature 401: 33-34, 1999.
11. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME: Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 91: 231-41, 1997.
12. Brunei A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 98: 857-66, 1999.
13. Cardone MH, Roy N, Stennicke HR, Salvasen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-21, 1998.
14. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase 3 by insulin mediated by protein kinase B. Nature 378: 785-89, 1995.
15. Bellacosa A, Testa JR, Staal SP and Tsichlis PN: A retroviral oncogene, akt, encoding a serine threonine kinase containing a SH2-like region. Science 254: 274-277, 1991.
16. Jones PF, Jakubowicz T, Pitossi FJ, Maurer F and Hemmings BA: Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci 88: 4171-4175, 1991.
17. Coffer PJ and Woodgett JR: Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem 201: 475-481, 1991.
18. Masuer S, Haefner B, Wesselink J, Hoefnagel E, Mortier E, Verhasselt AT, Gordon R and Richardson A: Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. Eur J Biochem 265: 353-360, 1999.
19. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN and Testa JR: Akt2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci 89: 9267-71, 1992.
20. Sun M, Wang G, Paciga JE, Feldman RI, Yuan Z, Ma X, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ: Akt1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Amer J Path 159: 431-37, 2001.
21. Cheng JQ, Rugged B, Klein WM, Sonoda G, Altomare DA, Warson DK and Testa JR: Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci 93: 3636-41, 1996.
22. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth R: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528-21532, 1999.
23. Stambolic V, Suzuki A, Pompa J, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39, 1998.
24. Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL: The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci 95: 15587-91, 1998.
25. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puz J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanelia BC et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancers. Science 275: 1943-47, 1997.
26. Liu X, Shi Yan, Man E, Chen Z, Rosenberg SH, Giranda V, Luo Y and Ng S: Down-regulation of Akt1 inhibits anchorage-independent cell growth and induces apoptosis in cancer cells. Neoplasia 3: 278-86, 2001.
27. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB and Schreiber SL: Control of the p70 S6 kinase activity of FRAP in vivo. Nature 577: 441-46, 1995.
28. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS and Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 569: 756-758, 1994.
29. Raught B, Gingras A and Sonenberg N: The target of rapamycin (TOR) proteins. Proc Natl Acad Sci 98: 7037-44, 2001.
30. s6k. EMBO J 16: 3693-04, 1997.
31. Aoki M, Blazek E and Vogt P: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3K and Akt. Proc Natl Acad Sci 98: 136-41, 2001.
32. Manning BD, Tee AR, Logsdon MN, Blenis J and Cantley LC: Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Mol Cell 10: 151-62, 2002.
33. Inoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR . signalling. Nat Cell Biol 4: 648-57, 2002.
34. Potter CJ, Pedraza LG and Xu T: Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4: 658-65, 2002.
35. Dan HC, Sun M, Yang L, Feldman RI, Sui XM, Ou CC, Nellist M, Yeung RS, Halley DJ, Nicosia SV, Pledger WJ and Cheng JQ: Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem 277: 35364-70, 2002.
36. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers C: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci 98: 10314-10319, 2001.
37. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbachm V et al: An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/- mice. Proc Natl Acad Sci 98: 10320-25, 2001.
38. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W and Lichtenstein A: Enhanced sensitivity of multiple myeloma cells containing PTEN mutation to CCI-779. Cancer Res 62: 5027-34, 2002.
39. Noh W, Mondesire WH, Peng J, Jian W, Zhang H, Dong J and Mills GB: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10: 1013-1023, 2004.
40. Davies SP, Reddy H, Caivano M and Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
41. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC and Abraham RT: Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15: 5256-67, 1996.
42. Cho H, Mu J, Kim JK, Thovaldsen JL, Chu Q, Crenshaw III EB, Kastner KH, Bartolomer MS, Shulman GI and Birnbaum MJ: Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292: 1728-31, 2001.
43. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T and Hay N: Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Gene & Dev 15: 2203-2208, 2001.
44. Cho H, Thorvaldsen JL, Chu Q, Feng F and Birnbaum M: Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349-52, 2001.
45. Garofalo RS, Orena SJ, Rafidi K, Torchia AJ, Stock JL, Hildebrandt AL, Coskran T, Black S, Brees DJ, Wicks JR, McNeish JD and Coleman KG: Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J Clinc Invest 112: 197-208, 2003.
46. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jakobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG and Hay N: Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Gene & Dev 17: 1352-65, 2003.